Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 GSK Shuts Down NC Plant | Contract Pharma

What are you searching for?

Sign in
Breaking News

GSK Shuts Down NC Plant

Discovers the bacteria that causes Legionnaires’ disease

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

GlaxoSmithKline shut down its plant in Zebulon, NC on Tuesday after discovering the bacteria that causes Legionnaires’ disease in a self-standing cooling tower. The plant produces inhaled drugs including asthma drug Advair, and contracts with other pharmaceutical companies to produce their drugs. The company said in a statement that the cooling tower “does not come into contact with product manufactured at the facility.”
 
Approximately 400 of the 850 employees at the Zebulon facility were told to stay away until the towers are cleaned. The FDA is checking into reports of the bacteria’s discovery. State and county health officials said they weren’t aware of any Legionnaire’s disease cases associated with the Glaxo facility, adding that most people who are exposed to the bacteria don’t become ill.
 
“We are trying to gather information on what the situation is,” said GSK spokeswoman Jenni Brewer Ligday. “It was found during routine testing, so we’re trying to get a better handle of how often those tests are conducted, also more details on whether product has been impacted and, if they have, what is our procedure in place to handle that.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters